Oramed to Present at Jefferies Global Healthcare Conference on June 2 in New York City PR Newswire JERUSALEM, May 27, 2014 JERUSALEM, May 27, 2014 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (www.oramed.com),a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that Nadav Kidron, the Company's Chief Executive Officer, will deliver a corporate presentation at the Jefferies Global Healthcare Conference taking place from June 2-5, 2014, in New York City. Presentation Details Jefferies Global Healthcare Conference Date: Monday, June 2, 2014 Time: 9:30am EDT A live webcast of the presentation can be viewed at http://wsw.com/webcast/jeff82/ORMP and will be archived for an additional 90 days. About The Jefferies Global Healthcare Conference The conference will feature an extensive range of public & private healthcare companies across the biopharmaceuticals, life sciences, healthcare services, healthcare IT and medical technology sectors. This global gathering of leading executives, institutional investors, private equity investors and VCs will address near- and long-term investment opportunities and discuss the mechanisms driving healthcare in the U.S. and internationally. The four- day conference will be comprised of company presentations, Q&A breakout sessions, keynotes and thematic panels. Company management teams and investors will also have the opportunity to participate in 1x1 and small group meetings. About Oramed Pharmaceuticals Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, Oramed's Protein Oral Delivery (POD^TM) technology is based on over 30 years of research by top research scientists at Jerusalem'sHadassah Medical Center. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary flagship product, an orally ingestible insulin capsule (ORMD-0801) currently in separate Phase II clinical trials in patients with both type 1 and type 2 diabetes under an Investigational New Drug application with the U.S. FDA, and with its oral GLP-1 analog capsule (ORMD-0901) entering IND-enabling studies later this year. For more information, the content of which is not part of this press release, please visit: www.oramed.com Forward-looking statements: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates" and similar expressions or variations of such words are intended to identify forward-looking statements. For example, we are using forward-looking statements when we discuss our clinical trials, including the expected design or timing thereof and revolutionizing the treatment of diabetes with our products. These forward-looking statements are based on the current expectations of the management of Oramed only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval or patent protection for our product candidates; competition from other pharmaceutical or biotechnology companies; and our ability to obtain additional funding required to conduct our research, development and commercialization activities. In addition, the following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; delays or obstacles in launching our clinical trials; changes in legislation; inability to timely develop and introduce new technologies, products and applications; lack of validation of our technology as we progress further and lack of acceptance of our methods by the scientific community; inability to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties that may develop with our process; greater cost of final product than anticipated; loss of market share and pressure on pricing resulting from competition; laboratory results that do not translate to equally good results in real settings; our patents may not be sufficient; and final that products may harm recipients, all of which could cause the actual results or performance of Oramed to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Oramed undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Oramed, reference is made to Oramed's reports filed from time to time with the Securities and Exchange Commission. Company Contact: US Investor Relations Oramed Pharmaceuticals Contact: Aviva Guiloff LifeSci Advisors LLC Office: +972-2-566-0001 ext. 2 Andrew McDonald US: 1-718-831-2512 ext. 2 US: 1-646-597-6987 Email: email@example.com Email: firstname.lastname@example.org SOURCE Oramed Pharmaceuticals Inc. Website: http://www.oramed.com
CDC Confirms First Ebola Case Diagnosed in the United States
Oramed to Present at Jefferies Global Healthcare Conference on June 2 in New York City
Press spacebar to pause and continue. Press esc to stop.